Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6530
    +0.0007 (+0.11%)
     

  • OIL

    84.02
    +0.45 (+0.54%)
     

  • GOLD

    2,345.50
    +3.00 (+0.13%)
     

  • Bitcoin AUD

    97,401.44
    -860.68 (-0.88%)
     

  • CMC Crypto 200

    1,325.96
    -70.57 (-5.05%)
     

  • AUD/EUR

    0.6104
    +0.0031 (+0.51%)
     

  • AUD/NZD

    1.0990
    +0.0032 (+0.30%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,737.42
    +306.92 (+1.76%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • Dow Jones

    38,277.36
    +191.56 (+0.50%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Kura Oncology to Participate in Upcoming Investor Conferences

Kura Oncology, Inc.
·2-min read
Kura Oncology, Inc.
Kura Oncology, Inc.

SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences:

  • A “Leukemia Corporate Panel” discussion at the Cowen Health Care Conference in Boston at 12:50 p.m. ET / 9:50 a.m. PT on March 8, 2023;

  • A fireside chat at the Cowen Health Care Conference at 2:50 p.m. ET / 11:50 a.m. PT on March 8, 2023; and

  • A fireside chat at the Barclays Global Healthcare Conference in Miami at 2:35 p.m. ET / 11:35 a.m. PT on March 14, 2023.

Live audio webcasts will be available in the Investors section of Kura’s website at www.kuraoncology.com, with archived replays available following the events.

ADVERTISEMENT

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors. For additional information, please visit Kura’s website at www.kuraoncology.com.

Contacts

Investors:
Pete De Spain
Senior Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Media:
Alexandra Weingarten
Senior Manager, Corporate Communications
(858) 500-8822
alexandra@kuraoncology.com